EA201390364A1 - Средство для лечения синдрома сухого глаза, характеризующееся комбинированием агониста рецептора pyи гиалуроновой кислоты или ее соли, способ лечения синдрома сухого глаза и применение агониста рецептора pyи гиалуроновой кислоты или ее соли - Google Patents

Средство для лечения синдрома сухого глаза, характеризующееся комбинированием агониста рецептора pyи гиалуроновой кислоты или ее соли, способ лечения синдрома сухого глаза и применение агониста рецептора pyи гиалуроновой кислоты или ее соли

Info

Publication number
EA201390364A1
EA201390364A1 EA201390364A EA201390364A EA201390364A1 EA 201390364 A1 EA201390364 A1 EA 201390364A1 EA 201390364 A EA201390364 A EA 201390364A EA 201390364 A EA201390364 A EA 201390364A EA 201390364 A1 EA201390364 A1 EA 201390364A1
Authority
EA
Eurasian Patent Office
Prior art keywords
therapeutically effective
dry eye
effective concentration
eye syndrome
treating
Prior art date
Application number
EA201390364A
Other languages
English (en)
Other versions
EA026680B1 (ru
Inventor
Юко Ситидзе
Ацуеси Дота
Такаси Нагано
Масацугу Накамура
Асука Сакамото
Original Assignee
Сантен Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сантен Фармасьютикал Ко., Лтд. filed Critical Сантен Фармасьютикал Ко., Лтд.
Publication of EA201390364A1 publication Critical patent/EA201390364A1/ru
Publication of EA026680B1 publication Critical patent/EA026680B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Средство для лечения синдрома сухого глаза, включающее комбинацию агониста рецептора PYв терапевтически эффективной концентрации и гиалуроновой кислоты или ее соли в терапевтически эффективной концентрации, где указанное средство имеет лекарственную форму офтальмического средства, может существенно стимулировать секрецию слезной жидкости и может существенно улучшать состояние при нарушениях эпителия роговицы и, как поэтому ожидают, будет новым средством для лечения синдрома сухого глаза.
EA201390364A 2010-09-10 2011-09-09 Средство для лечения синдрома сухого глаза, характеризующееся комбинированием агониста рецептора p2yи гиалуроновой кислоты или ее соли, способ лечения синдрома сухого глаза и применение агониста рецептора p2yи гиалуроновой кислоты или ее соли EA026680B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010203198 2010-09-10
PCT/JP2011/070578 WO2012033189A1 (ja) 2010-09-10 2011-09-09 Ｐ２ｙ2受容体作動薬およびヒアルロン酸またはその塩を組み合わせたことを特徴とするドライアイ治療剤、ドライアイの治療方法、ならびにその使用

Publications (2)

Publication Number Publication Date
EA201390364A1 true EA201390364A1 (ru) 2013-08-30
EA026680B1 EA026680B1 (ru) 2017-05-31

Family

ID=45810785

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390364A EA026680B1 (ru) 2010-09-10 2011-09-09 Средство для лечения синдрома сухого глаза, характеризующееся комбинированием агониста рецептора p2yи гиалуроновой кислоты или ее соли, способ лечения синдрома сухого глаза и применение агониста рецептора p2yи гиалуроновой кислоты или ее соли

Country Status (19)

Country Link
US (1) US9006208B2 (ru)
EP (1) EP2614838B1 (ru)
JP (1) JP5956735B2 (ru)
KR (2) KR101707269B1 (ru)
CN (2) CN106729718A (ru)
AU (2) AU2011299851A1 (ru)
BR (1) BR112013005438B1 (ru)
CA (1) CA2810481C (ru)
DK (1) DK2614838T3 (ru)
EA (1) EA026680B1 (ru)
ES (1) ES2569246T3 (ru)
HK (1) HK1184686A1 (ru)
MX (1) MX336944B (ru)
MY (1) MY170198A (ru)
NZ (1) NZ608202A (ru)
PL (1) PL2614838T3 (ru)
SG (1) SG188482A1 (ru)
TW (1) TWI519301B (ru)
WO (1) WO2012033189A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2659894A4 (en) * 2010-12-28 2014-12-10 Santen Pharmaceutical Co Ltd OPHTHALMIC SOLUTION WITH DIQUAFOSOL, METHOD OF MANUFACTURING THEREOF, AND METHOD FOR PREVENTING THE FORMATION OF INSOLUBLE LOW-HIT
UA113981C2 (xx) 2012-03-26 2017-04-10 Офтальмологічний розчин, що містить диквафасол
PT3019177T (pt) 2013-07-10 2020-12-30 Matrix Biology Inst Composições de hialuronano de elevada elasticidade e suas utilizações
US9289494B2 (en) 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions
JP6267003B2 (ja) * 2014-02-27 2018-01-24 参天製薬株式会社 ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
KR20180014768A (ko) * 2015-06-05 2018-02-09 산텐 세이야꾸 가부시키가이샤 소프트 콘택트렌즈가 착용된 드라이아이 환자의 눈에 점안되도록 이용되는 것을 특징으로 하는 드라이아이 치료제
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
CN108135926A (zh) 2015-09-24 2018-06-08 基质生物研究所 高弹性透明质酸组合物及其使用方法
US20190240251A1 (en) * 2016-10-14 2019-08-08 i.com medical GmbH Method for establishing, restoring, and preserving homeostasis of the ocular surface
JPWO2018074421A1 (ja) 2016-10-21 2019-08-29 ライオン株式会社 眼科用剤及び眼科用薬
CN107096016B (zh) * 2017-06-26 2021-04-06 蒋广伟 一种缓解视力疲劳的滴液
RU2652581C1 (ru) * 2017-07-03 2018-04-26 федеральное государственное бюджетное образовательное учреждение высшего образования "Приволжский исследовательский медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения роговично-конъюнктивального ксероза
KR102108552B1 (ko) * 2018-05-15 2020-05-08 한국세라믹기술원 히알루론산 마이크로비드의 제조 방법 및 상기 히알루론산 마이크로비드의 용도
CN109260146A (zh) * 2018-10-12 2019-01-25 广州大光制药有限公司 地夸磷索钠眼用即用型凝胶滴眼液及制备方法
JPWO2020175525A1 (ja) 2019-02-27 2021-12-23 参天製薬株式会社 ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
WO2021039748A1 (ja) * 2019-08-27 2021-03-04 参天製薬株式会社 ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01115902A (ja) 1987-10-30 1989-05-09 Showa Sangyo Co Ltd ヒアルロン酸の製造法
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
DK0981534T3 (da) 1997-02-06 2006-09-04 Inspire Pharmaceuticals Inc Dinukleotider og deres anvendelser
US7223744B2 (en) 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
JP3723227B2 (ja) 1997-07-25 2005-12-07 インスパイアー ファーマシューティカルズ，インコーポレイティド ジ（ウリジン５’）−テトラホスフェート及びその塩の大規模生産のための方法
JP2003160491A (ja) 2001-09-11 2003-06-03 Santen Pharmaceut Co Ltd ジウリジンリン酸含有点眼液

Also Published As

Publication number Publication date
CN103096929A (zh) 2013-05-08
MX2013002677A (es) 2013-06-13
TW201216971A (en) 2012-05-01
KR20170018462A (ko) 2017-02-17
SG188482A1 (en) 2013-04-30
PL2614838T3 (pl) 2016-10-31
MX336944B (es) 2016-02-03
HK1184686A1 (zh) 2014-01-30
US9006208B2 (en) 2015-04-14
CN106729718A (zh) 2017-05-31
AU2011299851A1 (en) 2013-04-04
KR101707269B1 (ko) 2017-02-15
US20130172287A1 (en) 2013-07-04
BR112013005438B1 (pt) 2021-09-21
JP5956735B2 (ja) 2016-07-27
TWI519301B (zh) 2016-02-01
AU2017200821B2 (en) 2018-08-30
WO2012033189A1 (ja) 2012-03-15
NZ608202A (en) 2014-08-29
CA2810481C (en) 2018-06-19
ES2569246T3 (es) 2016-05-09
BR112013005438A2 (pt) 2016-05-17
EP2614838A1 (en) 2013-07-17
MY170198A (en) 2019-07-09
EP2614838A4 (en) 2014-02-26
CA2810481A1 (en) 2012-03-15
EA026680B1 (ru) 2017-05-31
JP2012077080A (ja) 2012-04-19
AU2017200821A1 (en) 2017-03-02
KR20130109130A (ko) 2013-10-07
EP2614838B1 (en) 2016-04-20
DK2614838T3 (en) 2016-05-02

Similar Documents

Publication Publication Date Title
EA201390364A1 (ru) Средство для лечения синдрома сухого глаза, характеризующееся комбинированием агониста рецептора pyи гиалуроновой кислоты или ее соли, способ лечения синдрома сухого глаза и применение агониста рецептора pyи гиалуроновой кислоты или ее соли
CL2017002527A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares. (divisional de solicitud n°2485-2015).
NZ704247A (en) Compositions and treatment for eye diseases and disorders
EA201500364A1 (ru) Лечение глазных заболеваний
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
BR112013029713A2 (pt) método de tratamento de distúrbios da visão
EA201690212A8 (ru) Способы лечения или профилактики офтальмологических патологических состояний
EA201491773A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата
EA201591290A3 (ru) Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3
NZ727516A (en) Treatment of ocular neovascularization using a recombinant virus containing a nucleic acid encoding a vegf inhibitor
MX351230B (es) Formulacion oftalmica y metodo para mitigar la presbicia.
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
EA201691402A1 (ru) Фармацевтический препарат, содержащий соединение пиридиламиноуксусной кислоты
MA33991B1 (fr) Procede de traitement des troubles de l'angiogenese oculaire ou de la fuite vasculaire
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
NZ704178A (en) Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
MX355770B (es) Composicion farmaceutica de ibuprofeno y tramadol para uso oftalmico.
EA201501166A1 (ru) Соединение гликозаминогликана, способ его получения и применение
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
BR112014004545A2 (pt) inibidores leves de rock
EA201370230A1 (ru) Новые ингибиторы rock
AR092842A1 (es) Tratamiento de enfermedades inflamatorias oculares usando laquinimod
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
EA201591123A1 (ru) Комбинации агониста glp1r и метформина, а также способ их применения при лечении диабета 2 типа и прочих расстройств
EA201390618A1 (ru) Режимы дозирования при лечении офтальмологического сосудистого заболевания

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM